ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

EP: 1.ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

EP: 2.ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

Now Viewing

EP: 3.ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

EP: 4.ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

Data from the following clinical trials are discussed:

• LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2-positive locally advanced or metastatic esophagogastric adenocarcinoma (EGA): Results of the randomized phase 2 INTEGA trial (INTEGA)
• LBA55 - Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric02)